No title
Background: We aimed to assess the risk of serious infections in patients with inflammatory bowel disease (IBD) exposed to different advanced therapies. Methods: We linked nationwide registers and compared rates of incident serious infections in patients with Crohn’s disease (CD) and ulcerative colitis (UC) exposed to medical therapies versus matched general population comparators during 2007-2023
